CEPIM1g Price

Overview

Welcome to Dwaey, specifically on CEPIM1g page.
This medicine contains an important and useful components, as it consists of
Cefipime + Arginine is available in the market in concentration

Name

Vaccine - Diphtheria antigen / Tetanus antigen / Pertussis antigen

Precaution

llergic history: Use caution in individuals with known hypersensitivity to any vaccine component, including neomycin or polymyxin B (if present). Febrile illness: Defer vaccination in individuals with moderate to severe acute illness with or without fever. Neurological conditions: Postpone in individuals with evolving neurological conditions (e.g., uncontrolled epilepsy, progressive encephalopathy) until condition stabilizes. Guillain-Barré Syndrome (GBS): Previous history of GBS within 6 weeks of receiving a vaccine containing tetanus toxoid is a precaution. Bleeding disorders: Use caution in patients with thrombocytopenia or coagulation disorders due to intramuscular injection risk. History of seizures or hypotonic-hyporesponsive episode: Monitor carefully, especially in infants.

Indication

This combination vaccine is indicated for the active immunization against diphtheria, tetanus, and pertussis: Primary vaccination series in infants and young children. Booster doses in older children, adolescents, and adults depending on national immunization schedules. Post-exposure prophylaxis when combined with tetanus immunoglobulin in high-risk wounds.

Contra indication

Known hypersensitivity to diphtheria, tetanus, or pertussis antigens, or any excipients. Anaphylactic reaction to a previous dose of DTP or related vaccine. Progressive neurologic disorder (e.g., uncontrolled epilepsy, infantile spasms). Occurrence of encephalopathy within 7 days of a previous dose not attributable to another identifiable cause.

Side Effect

Very common: Local pain, redness, swelling at injection site, fever, irritability, and drowsiness. Common: Vomiting, loss of appetite, persistent crying, mild rash. Uncommon to rare: Febrile seizures, hypotonic-hyporesponsive episodes, allergic reactions including urticaria. Serious adverse events: Anaphylaxis, encephalopathy (extremely rare), brachial neuritis (linked with tetanus toxoid in rare cases).

Pregnancy Category ID

Information not available

Mode of Action

Diphtheria toxoid stimulates the production of antibodies that neutralize the diphtheria exotoxin. Tetanus toxoid induces antitoxin antibodies that provide protection against the tetanus neurotoxin. Pertussis antigen (whole cell or acellular) triggers an immune response to Bordetella pertussis, preventing whooping cough. Immunity is achieved through activation of B cells and memory T cells, offering long-term protection.

Interaction

Immunosuppressive therapy (e.g., corticosteroids, chemotherapy) may reduce vaccine effectiveness. Other vaccines: Can be co-administered with MMR, IPV, and Hib vaccines; use separate injection sites. Antipyretics (e.g., paracetamol): May reduce post-vaccination fever but not recommended prophylactically unless indicated. Live vaccines: No known interaction, but ensure proper timing based on national guidelines.

Pregnancy Category Note

Considered safe during pregnancy, particularly Tdap formulations (Tetanus, Diphtheria, acellular Pertussis): Recommended during the second or third trimester to provide passive immunity to newborns. WHO and CDC endorse maternal Tdap to reduce pertussis morbidity and mortality in infants.

Adult Dose

Tdap (reduced diphtheria and pertussis): Single 0.5 mL intramuscular dose. Td booster: Every 10 years, or after wound exposure if >5 years since last dose. Catch-up vaccination: Based on immunization history and national guidelines.

Child Dose

Primary series: Three doses of 0.5 mL intramuscularly at 6, 10, and 14 weeks of age. Booster doses: At 15–18 months and 4–6 years of age. Follows Expanded Programme on Immunization (EPI) or country-specific schedule.

Renal Dose

No renal dose adjustment required. Safe in patients with renal impairment; immune response is unaffected.

Administration

Route: Intramuscular (IM) only. Site: Infants: Anterolateral aspect of the thigh. Children & adults: Deltoid muscle. Do not inject intravascularly or subcutaneously. Shake well before use; discard if particulate matter is present. Ensure proper cold chain storage: 2°C to 8°C. Use a sterile, single-use syringe and needle.